Search results for "BC"

showing 10 items of 1938 documents

Diverse relations between ABC transporters and lipids: An overview.

2016

It was first discovered in 1992 that P-glycoprotein (Pgp, ABCB1), an ATP binding cassette (ABC) transporter, can transport phospholipids such as phosphatidylcholine, -ethanolamine and -serine as well as glucosylceramide and glycosphingolipids. Subsequently, many other ABC transporters were identified to act as lipid transporters. For substrate transport by ABC transporters, typically a classic, alternating access model with an ATP-dependent conformational switch between a high and a low affinity substrate binding site is evoked. Transport of small hydrophilic substrates can easily be imagined this way, as the molecule can in principle enter and exit the transporter in the same orientation. …

0301 basic medicineModels MolecularATP Binding Cassette Transporter Subfamily BBiophysicsGene ExpressionATP-binding cassette transporterPhosphatidylserinesBiologyBiochemistrySubstrate SpecificitySerine03 medical and health sciencesLipid translocationHumansProtein IsoformsBinding siteLipid bilayerLipid TransportATP-binding domain of ABC transportersBinding SitesPhosphatidylethanolaminesFatty AcidsTransporterBiological TransportCell BiologyCell biology030104 developmental biologyBiochemistryPhosphatidylcholineslipids (amino acids peptides and proteins)Protein BindingBiochimica et biophysica acta. Biomembranes
researchProduct

Structure of AP205 Coat Protein Reveals Circular Permutation in ssRNA Bacteriophages.

2016

We are thankful to the MAX-lab staff for their support during our visit at the synchrotron.; International audience; AP205 is a single-stranded RNA bacteriophage that has a coat protein sequence not similar to any other known single-stranded RNA phage. Here, we report an atomic-resolution model of the AP205 virus-like particle based on a crystal structure of an unassembled coat protein dimer and a cryo-electron microscopy reconstruction of the assembled particle, together with secondary structure information from site-specific solid-state NMR data. The AP205 coat protein dimer adopts the conserved Leviviridae coat protein fold except for the N-terminal region, which forms a beta-hairpin in …

0301 basic medicineModels MolecularRNA bacteriophageViral proteinCryo-electron microscopyProtein Conformation010402 general chemistrymedicine.disease_causeCrystallography X-Ray01 natural sciencesvirus-like particleBacteriophage03 medical and health sciencesStructural Biology[CHIM.ANAL]Chemical Sciences/Analytical chemistryLeviviridaemedicineRNA VirusesBacteriophages[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]Molecular BiologyProtein secondary structurebiologyCryoelectron MicroscopyRNA[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologycircular permutationRNA PhagesCircular permutation in proteinsbiology.organism_classification3. Good health0104 chemical sciencesCrystallography030104 developmental biologycoat proteinBiophysicsLeviviridaeCapsid ProteinsJournal of molecular biology
researchProduct

Bax transmembrane domain interacts with prosurvival Bcl-2 proteins in biological membranes

2016

The Bcl-2 (B-cell lymphoma 2) protein Bax (Bcl-2 associated X, apoptosis regulator) can commit cells to apoptosis via outer mitochondrial membrane permeabilization. Bax activity is controlled in healthy cells by prosurvival Bcl-2 proteins. C-terminal Bax transmembrane domain interactions were implicated recently in Bax pore formation. Here, we show that the isolated transmembrane domains of Bax, Bcl-xL (B-cell lymphoma-extra large), and Bcl-2 can mediate interactions between Bax and prosurvival proteins inside the membrane in the absence of apoptotic stimuli. Bcl-2 protein transmembrane domains specifically homooligomerize and heterooligomerize in bacterial and mitochondrial membranes. Thei…

0301 basic medicineMultidisciplinary030102 biochemistry & molecular biologyChemistryApoptosis RegulatorapoptosisBiological membraneBiological SciencesBioinformaticsBiotecnologiaOuter mitochondrial membraneoligomerizationtransmembraneCell biologymitochondria03 medical and health sciencesTransmembrane domain030104 developmental biologyMembraneMembranes (Biologia)ApoptosisBcl-2ProteïnesProceedings of the National Academy of Sciences
researchProduct

An siRNA-based screen in C2C12 myoblasts identifies novel genes involved in myogenic differentiation

2017

International audience; AbstractMyogenesis is a highly regulated multi-step process involving myoblast proliferation and differentiation. Although studies over the last decades have identified several factors governing these distinct major phases, many of them are not yet known. In order to identify novel genes, we took advantage of the C2C12 myoblastic line to establish a functional siRNA screen combined with quantitative-imaging analysis of a large amount of differentiated myoblasts. We knocked down 100 preselected mouse genes without a previously characterized role in muscle. Using image analysis, we tracked gene-silencing phenotypes by quantitative assessment of cellular density, myotub…

0301 basic medicineMyoblast proliferationMuscle Fibers SkeletalProliferation[SDV.BC]Life Sciences [q-bio]/Cellular BiologyBiologyMuscle DevelopmentCell LineMyoblastsNovel geneMice03 medical and health sciences0302 clinical medicineRNA interferenceAnimalsMyocyteGenetic TestingRNA Small InterferingGeneCell NucleusGeneticsMyogenesis[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyMyogenesisCell DifferentiationCell BiologyPhenotypeCell biologyPhenotype030104 developmental biologyScreenDifferentiationsiRNARNA InterferenceC2C12C2C12030217 neurology & neurosurgery
researchProduct

Levosimendan protects human hepatocytes from ischemia-reperfusion injury.

2017

Background Ischemia-reperfusion injury (IRI) is a major challenge in liver transplantation. The mitochondrial pathway plays a pivotal role in hepatic IRI. Levosimendan, a calcium channel sensitizer, was shown to attenuate apoptosis after IRI in animal livers. The aim of this study was to investigate the effect of levosimendan on apoptosis in human hepatocytes. Methods Primary human hepatocytes were either exposed to hypoxia or cultured under normoxic conditions. After the hypoxic phase, reoxygenation was implemented and cells were treated with different concentrations of levosimendan (10ng/ml, 100ng/ml, 1000ng/ml). The overall metabolic activity of the cells was measured using 3-(4,5-dimeth…

0301 basic medicineNecrosisCritical Care and Emergency Medicinelcsh:MedicineApoptosis030204 cardiovascular system & hematologyBiochemistry0302 clinical medicineAnimal CellsMedicine and Health SciencesEnzyme assaysColorimetric assayslcsh:ScienceBioassays and physiological analysisCells CulturedEnergy-Producing Organellesbcl-2-Associated X ProteinMultidisciplinaryMTT assaybiologyCell DeathMitochondriaPyridazinesLiverCell ProcessesReperfusion Injurymedicine.symptomCellular TypesAnatomyCellular Structures and Organellesmedicine.drugResearch Articlemedicine.medical_specialtyCell PhysiologyIschemiaCardiologySurgical and Invasive Medical ProceduresBioenergetics03 medical and health sciencesDigestive System ProceduresBcl-2-associated X proteinInternal medicinemedicineHumansMTT assayddc:610SimendanHeart FailureTransplantationbusiness.industrylcsh:RHydrazonesBiology and Life SciencesLevosimendanCell BiologyOrgan TransplantationHypoxia (medical)medicine.diseaseLiver TransplantationCell MetabolismResearch and analysis methods030104 developmental biologyEndocrinologyApoptosisReperfusionBiochemical analysisbiology.proteinHepatocyteslcsh:QbusinessReperfusion injuryPloS one
researchProduct

Efficiency of Target Larvicides Is Conditioned by ABC-Mediated Transport in the Zoonotic Nematode Anisakis pegreffii

2018

Anisakiasis is among the most significant emerging foodborne parasitoses contracted through consumption of thermally unprocessed seafood harboring infective Anisakis species larvae. The efficacy of the currently applied anthelminthic therapy in humans and in model organisms has not proven sufficient, so alternative solutions employing natural compounds combined with chemical inhibitors should be explored. By testing toxicity of the natural monoterpenes nerolidol and farnesol and the conventional anthelminthics abamectin and levamisole in the presence/absence of MK-571 and Valspodar, which inhibit the ABC transporter proteins multidrug resistance protein (MRP-like) and P-glycoprotein (P-gp),…

0301 basic medicineNematodaAnisakis antiparasitic agents multidrug resistance proteinsAnisakiATP-binding cassette transporterAnisakiasisAnisakisMicrobiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMechanisms of ResistanceTubulinSettore AGR/20 - ZoocoltureAnimalsHumansPharmacology (medical)ATP Binding Cassette Transporter Subfamily B Member 1Settore BIO/06 - Anatomia Comparata E CitologiaNerolidolPharmacologybiologyAntiparasitic AgentsTransporterFarnesolbiology.organism_classificationAnisakis030104 developmental biologyInfectious DiseasesNematodechemistryLevamisole030220 oncology & carcinogenesisLarvaAbamectinATP-Binding Cassette TransportersEffluxABC transporterSesquiterpenes
researchProduct

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?

2016

IF 5.008; International audience; Anti-EGFR therapy and antiangiogenic therapies are used alone or in combination with chemotherapies to improve survival in metastatic colorectal cancer. However, it is unknown whether pretreatment with antiangiogenic therapy could impact on the efficacy of anti-EGFR therapy. We selected one hundred and twenty eight patients diagnosed with advanced colorectal cancer with a KRAS and NRAS unmutated tumor. These patients were treated with cetuximab or panitumumab alone or with chemotherapy as second or third-line. Univariate and multivariate Cox model analysis were performed to estimate the effect of a previous bevacizumab regimen on progression free survival a…

0301 basic medicineNeuroblastoma RAS viral oncogene homologOncologyMaleVascular Endothelial Growth Factor AColorectal cancerCetuximabAngiogenesis Inhibitorsmedicine.disease_causeTrialGTP PhosphohydrolasesRas mutations[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsDrug InteractionsAged 80 and overCetuximabPanitumumabAntibodies MonoclonalMiddle Aged3. Good healthErbB ReceptorsOncology030220 oncology & carcinogenesisFemaleKRASColorectal Neoplasms1st-Line treatmentmedicine.drugResearch PaperAdultSTAT3 Transcription Factormedicine.medical_specialtyBevacizumabAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologybevacizumabIrinotecanDisease-Free SurvivalTumor angiogenesisProto-Oncogene Proteins p21(ras)03 medical and health sciencesVEGFRInternal medicineCell Line TumormedicinePanitumumabHumansEndothelial growth-FactorChemotherapyProgression-free survivalAgedbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyMembrane Proteinsmetastatic colon cancerStat-3medicine.diseaseVascular Endothelial Growth Factor Receptor-2IrinotecanRandomized phase-III030104 developmental biologyanti-EGFR therapyFactor receptorCaco-2 Cellsbusiness
researchProduct

Bcl-xL knockout attenuates mitochondrial respiration and causes oxidative stress that is compensated by pentose phosphate pathway activity

2017

Bcl-xL is an anti-apoptotic protein that localizes to the outer mitochondrial membrane and influences mitochondrial bioenergetics by controlling Ca2+ influx into mitochondria. Here, we analyzed the effect of mitochondrial Bcl-xL on mitochondrial shape and function in knockout (KO), wild type and rescued mouse embryonic fibroblast cell lines. Mitochondria of KO cells were more fragmented, exhibited a reduced ATP concentration, and reduced oxidative phosphorylation (OXPHOS) suggesting an increased importance of ATP generation by other means. Under steady-state conditions, acidification of the growth medium as a readout for glycolysis was similar, but upon inhibition of ATP synthase with oligo…

0301 basic medicineOligomycinBioenergeticsOxidative phosphorylationBH4 DOMAINMitochondrionPentose phosphate pathwaymedicine.disease_causeBiochemistryCYTOCHROME-C03 medical and health scienceschemistry.chemical_compoundCHANNEL VDAC0302 clinical medicinePhysiology (medical)BCL-XLmedicineJournal ArticleGlycolysisRELEASEATP synthasebiologyGLUCOSE-METABOLISMFISSIONAPOPTOSIS030104 developmental biologyBiochemistrychemistryCELLSbiology.proteinMEMBRANE030217 neurology & neurosurgeryOxidative stressFree Radical Biology and Medicine
researchProduct

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors

2019

In Chronic Myeloid Leukemia (CML), successful treatment requires accurate molecular monitoring to evaluate disease response and provide timely interventions for patients failing to achieve the desired outcomes. We wanted to determine whether measuring BCR-ABL1 mRNA doubling-times (DTs) could distinguish inconsequential rises in the oncogene’s expression from resistance to tyrosine kinase inhibitors (TKIs). Thus, we retrospectively examined BCR-ABL1 evolution in 305 chronic-phase CML patients receiving imatinib mesylate (IM) as a first line treatment. Patients were subdivided in two groups: those with a confirmed rise in BCR-ABL1 transcripts without MR3.0 loss and those failing IM. We found …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyDisease ResponseChronic Myeloid LeukemiaBCR-ABL1/ABL1IShalving-timelcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinehemic and lymphatic diseasesBCR-ABL1/ABL1; IS; Chronic Myeloid Leukemia; Doubling-time; Halving-time; Tyrosine kinase inhibitorstyrosine kinase inhibitorsmedicineDoubling timeOriginal ResearchBCR-ABL1/ABL1Oncogenebusiness.industryMyeloid leukemialcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensDiscontinuationdoubling-time030104 developmental biologyImatinib mesylateOncology030220 oncology & carcinogenesisCohortISBCR-ABL1/ABL1 ISbusinessTyrosine kinaseFrontiers in Oncology
researchProduct

High BCR-ABL/GUS(IS) levels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib

2017

Abstract Purpose: The approval of second-generation tyrosine kinase inhibitors (TKIs) for the first-line treatment of chronic myeloid leukemia (CML) has generated an unmet need for baseline molecular parameters associated with inadequate imatinib responses. Experimental Design: We correlated BCR–ABL/GUSIS and BCR–ABL/ABL transcripts at diagnosis with the outcome—defined by the 2013 European LeukemiaNet recommendations—of 272 patients newly diagnosed with CML receiving imatinib 400 mg/daily. Applying receiver-operating characteristic curves, we defined BCR–ABL/GUSIS and BCR–ABL/ABL levels associated with lower probabilities of optimal response, failure-free (FFS), event-free (EFS), transform…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPathologyMyeloidBCR-ABL Diagnosis CMLDrug intolerance03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineDiagnosismedicineBCR-ABLCMLneoplasmsABLbusiness.industryCancerMyeloid leukemiaImatinibOncology cancer researchmedicine.diseaseLeukemia030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisbusinessTyrosine kinasemedicine.drug
researchProduct